Stephen Wolverton

  • 303 Citations
  • 10 h-Index
1985 …2019

Research output per year

If you made any changes in Pure these will be visible here soon.

Publications

Filter
Article

A survey of resident perceptions of effective teaching behaviors.

Wolverton, S. E. & Bosworth, M. F., May 1 1985, In : Family medicine. 17, 3, p. 106-108 3 p.

Research output: Contribution to journalArticle

35 Scopus citations

Dermatologic drug formulary: An American Academy of Dermatology white paper

Steger, J. W., Wolverton, S. E., Greenberg, R. D., Ling, M. R., Resnick, S. D. & James, W. D., Jan 1996, In : Journal of the American Academy of Dermatology. 34, 1, p. 99-109 11 p.

Research output: Contribution to journalArticle

7 Scopus citations

Drug hypersensitivity syndrome in a patient receiving vismodegib

Lam, T., Wolverton, S. E. & Davis, C. L., Mar 2014, In : Journal of the American Academy of Dermatology. 70, 3, p. e65-e66

Research output: Contribution to journalArticle

8 Scopus citations

Major adverse effects from systemic drugs: Defining the risks

Wolverton, S., 1995, In : Current Problems in Dermatology (United States). 7, 1, p. 6-38 33 p.

Research output: Contribution to journalArticle

10 Scopus citations

Medical Malpractice in Dermatology—Part I: Reducing the Risks of a Lawsuit

Shah, V. V., Kapp, M. B. & Wolverton, S., Dec 1 2016, In : American Journal of Clinical Dermatology. 17, 6, p. 593-600 8 p.

Research output: Contribution to journalArticle

1 Scopus citations

Medical Malpractice in Dermatology—Part II:  What To Do Once You Have Been Served with a Lawsuit

Shah, V. V., Kapp, M. B. & Wolverton, S., Dec 1 2016, In : American Journal of Clinical Dermatology. 17, 6, p. 601-607 7 p.

Research output: Contribution to journalArticle

Monitoring for adverse effects from systemic drugs used in dermatology

Wolverton, S. E., Jan 1 1992, In : Journal of the American Academy of Dermatology. 26, 5, p. 661-679 19 p.

Research output: Contribution to journalArticle

25 Scopus citations

Moxifloxacin-induced drug hypersensitivity syndrome with features of toxic epidermal necrolysis

Weaver, C. H., Huddleston, H. M., Kingsley, M. M. & Wolverton, S. E., Nov 1 2009, In : Journal of Drugs in Dermatology. 8, 11, p. 1031-1033 3 p.

Research output: Contribution to journalArticle

8 Scopus citations

Multiple keratoacanthomas occurring in surgical margins and de novo treated with intralesional methotrexate

Veerula, V. L., Ezra, N., Aouthmany, M., Graham, T. A., Wolverton, S. & Somani, A-K., 2016, In : Cutis. 98, 6, p. E12-E15

Research output: Contribution to journalArticle

3 Scopus citations

Pemphigus foliaceus with epidermal detachment: Adverse events from patch testing

Cocklin, C. L., Shackelford, K., Wolverton, S. E. & Fett, D. D., Mar 1 2006, In : Dermatitis. 17, 1, p. 32-35 4 p.

Research output: Contribution to journalArticle

1 Scopus citations

Pyoderma gangrenosum: A presenting sign of myelodysplastic syndrome in undiagnosed fanconi anemia

Kandula, P., Shah, K. M., Wolverton, J. E., Le, C. & Wolverton, S., Jan 1 2019, In : Dermatology Online Journal. 25, 1

Research output: Contribution to journalArticle

1 Scopus citations

Recent trends in systemic psoriasis treatment costs

Beyer, V. & Wolverton, S. E., Jan 1 2010, In : Archives of Dermatology. 146, 1, p. 46-54 9 p.

Research output: Contribution to journalArticle

66 Scopus citations

Systemic Drug Therapy for Psoriasis: The Most Critical Issues

Wolverton, S. E., Apr 1991, In : Archives of Dermatology. 127, 4, p. 565-568 4 p.

Research output: Contribution to journalArticle

6 Scopus citations

The Muir-Torre syndrome in a black patient with AIDS: Histopathology and molecular genetic studies

Warschau, K. E., Eble, J. N., Hood, A. F., Wolverton, S. E. & Halling, K. C., 1997, In : Journal of Cutaneous Pathology. 24, 8, p. 511-518 8 p.

Research output: Contribution to journalArticle

19 Scopus citations